Atypical Burkitt Burkitt-like Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-06-11
Clinical Trial Update: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating Dose Adjusted EPOCH combined with either ofatumumab or rituximab in newly diagnosed or relapsed/refractory Burkitt …